Pedro A Torres-Saavedra
Overview
Explore the profile of Pedro A Torres-Saavedra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
50
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bandos H, Torres-Saavedra P, Culakova E, Gunn H, Lee M, Duan F, et al.
J Natl Cancer Inst Monogr
. 2025 Feb;
2025(68):14-21.
PMID: 39989038
Patient-reported outcomes (PROs) are often collected in cancer clinical trials. Data obtained from trials with PROs are essential in evaluating participant experiences relating to symptoms, financial toxicity, or health-related quality...
2.
Machtay M, Torres-Saavedra P, Thorstad W, Nguyen-Tan P, Siu L, Holsinger F, et al.
J Clin Oncol
. 2025 Jan;
JCO2401829.
PMID: 39841939
Purpose: Radiotherapy (RT)/cetuximab (C) demonstrated superiority over RT alone for locally advanced squamous head and neck cancer. We tested this in completely resected, intermediate-risk cancer. Methods: Patients had squamous cell...
3.
Guan L, Torres-Saavedra P, Zhao X, Major M, Holmes B, Nguyen N, et al.
Clin Cancer Res
. 2024 Dec;
PMID: 39656603
Purpose: NFE2L2/KEAP1/CUL3 mutations have been validated for radiation resistance in cell-based assays and animal models. However, clinical validation of these biomarkers has been challenging due to multimodality treatment regimens. This...
4.
Mell L, Torres-Saavedra P, Wong S, Kish J, Chang S, Jordan R, et al.
Lancet Oncol
. 2024 Nov;
25(12):1576-1588.
PMID: 39551064
Background: Management of patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) when cisplatin is contraindicated is controversial. We aimed to assess whether radiotherapy with concurrent and adjuvant...
5.
Zumsteg Z, Sheth S, Jabbour S, Patel K, Kimple R, Williams T, et al.
Lancet Oncol
. 2024 Oct;
25(10):e489-e500.
PMID: 39362260
NRG Oncology's Developmental Therapeutics and Radiation Therapy Subcommittee assembled an interdisciplinary group of investigators to address barriers to successful early phase clinical trials of novel combination therapies involving radiation. This...
6.
Wong S, Torres-Saavedra P, Saba N, Shenouda G, Bumpous J, Wallace R, et al.
JAMA Oncol
. 2023 Sep;
9(11):1565-1573.
PMID: 37768670
Importance: Patients with locally advanced non-human papillomavirus (HPV) head and neck cancer (HNC) carry an unfavorable prognosis. Chemoradiotherapy (CRT) with cisplatin or anti-epidermal growth factor receptor (EGFR) antibody improves overall...
7.
Wang D, Harris J, Kraybill W, Eisenberg B, Kirsch D, Ettinger D, et al.
JAMA Oncol
. 2023 Mar;
9(5):646-655.
PMID: 36995690
Importance: Pathologic complete response (pCR) may be associated with prognosis in patients with soft tissue sarcoma (STS). Objective: We sought to determine the prognostic significance of pCR on survival outcomes...
8.
Sherman E, Harris J, Bible K, Xia P, Ghossein R, Chung C, et al.
Lancet Oncol
. 2023 Jan;
24(2):175-186.
PMID: 36681089
Background: Anaplastic thyroid cancer is a rare and aggressive cancer with no standard radiotherapy-based local treatment. Based on data suggesting synergy between pazopanib and paclitaxel in anaplastic thyroid cancer, NRG...
9.
Caudell J, Torres-Saavedra P, Rosenthal D, Axelrod R, Nguyen-Tan P, Sherman E, et al.
Int J Radiat Oncol Biol Phys
. 2022 Dec;
116(3):533-543.
PMID: 36549347
Purpose: The combination of cisplatin and radiation or cetuximab and radiation improves overall survival of patients with locoregionally advanced head and neck carcinoma. NRG Oncology conducted a phase 3 trial...
10.
Michikawa C, Torres-Saavedra P, Silver N, Harari P, Kies M, Rosenthal D, et al.
Adv Radiat Oncol
. 2022 Nov;
7(6):100989.
PMID: 36420184
Purpose: An evolutionary action scoring algorithm (EAp53) based on phylogenetic sequence variations stratifies patients with head and neck squamous cell carcinoma (HNSCC) bearing missense mutations as high-risk, associated with poor...